CHINA China investigating HIV-contaminated blood plasma treatment

CHINA

China investigating HIV-contaminated blood plasma treatment

CGTN

03:19, February 08, 2019

(Photo: CGTN)

China has ordered a probe after a large batch of blood plasma was reportedly found to be contaminated with human immunodeficiency viruses (HIV).

State-owned Shanghai Xinxing Pharmaceutical Company, the country's second largest pharmaceutical manufacturing firm, sold more than 12,000 units of intravenous immunoglobulin. The product used for immune therapy treatment is made with antibodies from blood plasma.

In a swift response, the National Health Commission (NHC) and Shanghai Food and Drug Administration, ordered to recall the entire batch (number: 20180610Z) of intravenous immunoglobulin.

Health officials have been directed to closely monitor the patients that were administered the infected blood plasma, a statement released by the National Health Commission (NHC) said. 

On Wednesday, the NHC initiated an investigation into the tainted blood plasma batch. The HIV antibodies in the 50ml vials of the product were first detected by the Jiangxi Provincial Center for Disease Control and Prevention.

Intravenous immunoglobulin, a blood product, prepared from the serum of between 1,000 and 15,000 donors per batch is used for the treatment of low immunity that is triggered by conditions like blood cancer and hepatitis. 

In case "a positive HIV antibody were detected in blood products, it means that it has been contaminated by blood from HIV-positive people," Wang Yuedan, a doctor from Peking University Health Science Center, told The Beijing News.

The NHC, citing international medical literature and findings, maintained chances of contracting HIV infection are extremely low for patients that have been administered the contaminated blood plasma.

In recent months, incidents of tainted pharmaceutical products have increased in the country leading to a robust monitoring process.

Recently, more than 100 children were administered expired polio vaccines. Months earlier, faulty diphtheria, tetanus and whooping cough vaccines resulted in the government slapping a record penalty of an equivalent of 1.3 billion U.S. dollars on the vaccine manufacturer, Changchun Changsheng Biotechnology Company.

Last July, more than 250,000 contaminated rabies vaccines were produced by one of the country's largest vaccine producers. The government ordered an inquiry, fined the company an equivalent of 1.7 million U.S. dollars and revoked the its licence.


Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue